Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$148.98 USD
-3.69 (-2.42%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $148.88 -0.10 (-0.07%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$148.98 USD
-3.69 (-2.42%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $148.88 -0.10 (-0.07%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Zacks News
Sarepta (SRPT) Q2 Earnings Miss, DMD Drugs' Sales Robust
by Zacks Equity Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts the top line in the second quarter. However, the wider-than-anticipated losses drive the stock down in after-market trading.
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -147.66% and 6.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q2 Earnings on Aug 2: GILD, INCY & More
by Zacks Equity Research
Let's check out how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Aug 2.
Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.2% Jump Turn into More Strength?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Analysts Estimate Codexis (CDXS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Roche (RHHBY) 1H22 Earnings, Sales Grow, View Disappoints
by Zacks Equity Research
Roche (RHHBY) performance in the first half was decent on demand for its diagnostics base business and new drugs. Demand for COVID-19 tests is likely to fall in the second half.
Incyte (INCY) Gets FDA Nod for Label Expansion of Opzelura
by Zacks Equity Research
Incyte (INCY) Opzelura cream 1.5% gets FDA approval for another indication - nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
Novartis (NVS) Q2 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Novartis (NVS) reports mixed results in the second quarter, as key brands maintain momentum but generic competition remains a drag.
Roche (RHHBY) Announces 2-Year Data on Vabysmo for nAMD
by Zacks Equity Research
Roche's (RHHBY) new two-year data reinforce the long-term efficacy, safety and durability of Vabysmo in wet age-related mtacular degeneration.
NexImmune (NEXI) IND Gets Clearance for HPV-Related Cancer Drug
by Zacks Equity Research
NexImmune (NEXI) gets FDA clearance for IND for drug for human papillomavirus (HPV)-related cancers.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Pluristem (PSTI) Phase III Study Misses Goal, Stock Down
by Zacks Equity Research
Pluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating PLX-PAD cells did not meet the primary endpoint. Consequently, the stock declines.
Here's Why Sarepta Therapeutics (SRPT) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Sarepta Therapeutics (SRPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Sarepta (SRPT) Down on Clinical Hold on DMD Candidate SRP-5051
by Zacks Equity Research
The FDA places Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, on clinical hold, following a report of hypomagnesemia in the ongoing phase II MOMENTUM study.
Why Is Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bausch (BHC) Q1 Earnings and Revenues Miss, Stock Down
by Zacks Equity Research
Bausch (BHC) misses on earnings and sales in the first quarter due to incremental macro pressures and a challenging supply chain environment.
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q1
by Zacks Equity Research
Bayer (BAYRY) beats estimates for both earnings and revenues in the first quarter of 2022.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Sarepta (SRPT) Q1 Earnings Beat, DMD Drugs' Sales Robust
by Zacks Equity Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the first quarter. Stock up in after-market trading.
Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 11.11% and 3.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Sarepta Therapeutics (SRPT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Sarepta Therapeutics (SRPT) Down 1.2% Since Last Earnings Report?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT